Expert Notes Positive Trend Toward Improving Health Equity in Cancer Care

Commentary
Video

Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.

Initiatives such as Medicaid paying for clinical trials and reimbursement policies from the Centers for Medicare & Medicaid Services may be “game changers” for moving towards health equity in oncology, according to Robert A. Winn, MD.

Winn, director and Lipman Chair in Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, senior associate for Cancer Innovation, and professor of Pulmonary Disease and Critical Cancer Medicine at VCU School of Medicine, spoke about the trends in oncology he is seeing and what clinicians can do to bring equity to their institutions and community centers.

He noted that there is still work to be done all around for everyone to have access to the latest cancer care, including progress in biomarker testing for patients with lung cancer and other disease types. As a whole, however, he suggested that the community is heading in the right direction.

Transcript:

Several things on the horizon may be game changers for improving and moving towards equity. For example, the fact that at some point, we allowed Medicaid to pay for clinical trials. This new ruling by the Centers for Medicare & Medicaid Services [CMS] to allow for the reimbursements of navigation, i.e. getting people to navigate you from point A to point B, will also aid and assist us in getting towards a more equitable society in the context of oncology. There’s still work to do. We will always talk about when new drugs come out. There is usually a sort of non-intentional divide. For example, when immunotherapy came out, we wrote about this in the New York Times and everywhere else about the immunotherapy divide. New therapies, new technologies, and new screening mechanisms usually don’t tend to reach all communities equitably. That’s still a struggle. We are making some good progress, but we need to make more progress in the area of biomarker testing, for example, in lung cancer and all these other [cancers]. With the reimbursements of the CMS, Medicaid paying for clinical trials, and many other things that we could talk about, we are trending towards the health equity goal. We’re not there yet.

Reference

CMS finalizes physician payment rule that advances health equity. News release. Centers for Medicare & Medicaid Services. November 2, 2023. Accessed February 19, 2024. http://tinyurl.com/4p7dhr7h

Recent Videos
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.